Atossa Genetics (ATOS) Reports FDA Approval of Oral Endoxifen for 'Expanded Access' as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient
Tweet Send to a Friend
Atossa Genetics Inc. (NASDAQ: ATOS) today announced that the FDA has issued a “Safe to Proceed” letter under their “expanded ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
